laprituximab emtansine (IMGN289) / ImmunoGen, AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
laprituximab emtansine (IMGN289) / AbbVie
NCT01963715: A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Terminated
1
20
US
IMGN289
ImmunoGen, Inc.
EGFR Positive Solid Tumors
04/15
04/15

Download Options